SI2078022T1 - Spiro benzazepini, uporabljeni kot antagonisti vazopresina - Google Patents

Spiro benzazepini, uporabljeni kot antagonisti vazopresina

Info

Publication number
SI2078022T1
SI2078022T1 SI200730800T SI200730800T SI2078022T1 SI 2078022 T1 SI2078022 T1 SI 2078022T1 SI 200730800 T SI200730800 T SI 200730800T SI 200730800 T SI200730800 T SI 200730800T SI 2078022 T1 SI2078022 T1 SI 2078022T1
Authority
SI
Slovenia
Prior art keywords
renal
hyponatremia
hypertension
insufficiency
formula
Prior art date
Application number
SI200730800T
Other languages
English (en)
Inventor
Min A Xiang
Mona Patel
Philip Rybczynski
Joseph Gunnet
Keith T Demarest
Richard Look
Bruce Maryanoff
Michael J Costanzo
Stephen C Yabut
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI2078022T1 publication Critical patent/SI2078022T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
SI200730800T 2006-09-22 2007-09-19 Spiro benzazepini, uporabljeni kot antagonisti vazopresina SI2078022T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82665406P 2006-09-22 2006-09-22
EP07842799A EP2078022B1 (en) 2006-09-22 2007-09-19 Spiro benzazepines used as vasopressin antagonists
PCT/US2007/078917 WO2008036755A1 (en) 2006-09-22 2007-09-19 Spiro benzazepines used as vasopressin antagonists

Publications (1)

Publication Number Publication Date
SI2078022T1 true SI2078022T1 (sl) 2012-01-31

Family

ID=39030853

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730800T SI2078022T1 (sl) 2006-09-22 2007-09-19 Spiro benzazepini, uporabljeni kot antagonisti vazopresina

Country Status (14)

Country Link
US (1) US7825110B2 (sl)
EP (1) EP2078022B1 (sl)
JP (1) JP2010504351A (sl)
CN (1) CN101541806A (sl)
AT (1) ATE532786T1 (sl)
AU (1) AU2007299818B2 (sl)
CA (1) CA2665849A1 (sl)
CY (1) CY1112270T1 (sl)
DK (1) DK2078022T3 (sl)
ES (1) ES2374582T3 (sl)
PL (1) PL2078022T3 (sl)
PT (1) PT2078022E (sl)
SI (1) SI2078022T1 (sl)
WO (1) WO2008036755A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781521A4 (en) * 2011-10-19 2015-03-04 Kowa Co NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME
US10214520B2 (en) 2014-07-15 2019-02-26 Gruenenthal Gmbh Substituted azaspiro(4.5)decane derivatives
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
EP3321271A4 (en) 2015-07-07 2020-12-16 Japan Tobacco Inc. PROCESS FOR THE PREPARATION OF 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF
WO2018117152A1 (ja) * 2016-12-21 2018-06-28 日本たばこ産業株式会社 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその合成中間体
CN111295373A (zh) * 2017-09-15 2020-06-16 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
US20200337590A1 (en) 2018-01-16 2020-10-29 Bayer Aktiengesellschaft Assistance in the treatment of cardiac insufficiency
US20240101568A1 (en) * 2020-11-26 2024-03-28 Shanghai Jemincare Pharmaceutical Co., Ltd Novel benzazepine spiro derivative
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5985869A (en) 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
ES2089033T3 (es) 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
AU5292393A (en) 1992-10-07 1994-04-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
NZ523450A (en) 2000-07-05 2004-11-26 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin receptor antagonists
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7011898B2 (en) * 2003-03-21 2006-03-14 Air Products And Chemicals, Inc. Method of joining ITM materials using a partially or fully-transient liquid phase
BRPI0411598A (pt) 2003-06-17 2006-08-29 Janssen Pharmaceutica Nv espirobenzazepinas substituìdas
AU2004252135A1 (en) 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
CA2637838A1 (en) 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid

Also Published As

Publication number Publication date
PL2078022T3 (pl) 2012-04-30
CN101541806A (zh) 2009-09-23
CY1112270T1 (el) 2015-12-09
AU2007299818B2 (en) 2012-08-02
EP2078022B1 (en) 2011-11-09
ATE532786T1 (de) 2011-11-15
PT2078022E (pt) 2012-01-11
WO2008036755A1 (en) 2008-03-27
JP2010504351A (ja) 2010-02-12
EP2078022A1 (en) 2009-07-15
CA2665849A1 (en) 2008-03-27
DK2078022T3 (da) 2012-02-13
US7825110B2 (en) 2010-11-02
AU2007299818A1 (en) 2008-03-27
ES2374582T3 (es) 2012-02-20
US20080076753A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
PL2078022T3 (pl) Spirobenzoazepiny stosowane jako antagoniści wazopresyny
MY128065A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
CR8168A (es) Espirobenzazepinas sustituidas
WO2009089537A3 (en) Anti-cancer compounds
MX2012012902A (es) Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
MY147789A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
TWI316057B (en) Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
MX352548B (es) Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1.
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
ATE282621T1 (de) Indoloazepine als vasopressin rezeptor antagonisten
PE20140606A1 (es) Derivados de pirazol utiles como inhibidores de aldosterona sintasa
YU32702A (sh) Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
WO2007074130A3 (de) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1h)-on
MA34462B1 (fr) Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
PE20071234A1 (es) Composiciones a base de bh4 para el tratamiento de la enfermedad vascular
JP2012526773A5 (sl)
TN2013000050A1 (en) Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor